

SEQUENCE LISTING

<120> MURINE EXPRESSION OF HUMAN IG LAMBDA LOCUS

<140> PCT/GB99/03632

<141> 1999-11-03

<150> GB 9823930.4

<151> 1998-11-03

<160> 23

<170> PatentIn Ver. 2.1

<210> 1

<211> 29

<212> DNA

<213> Homo sapiens

<400> 1

aattctaaaa ctacaaactg cccccccca 29

<210> 2

<211> 21

<212> DNA

<213> HOMO SAPIENS

<400> 2

aattctaaaa ctacaaactg c 21

<210> 3

<211> 18

<212> DNA

<213> Homo sapiens

<400> 3

ctcccgggta gaagtcac 18

<210> 4

<211> 22

<212> DNA

<213> Homo sapiens

<400> 4

aattcgtgtg gccttggttg ct 22

<210> 5

<211> 234

<212> DNA

<213> HOMO SAPIENS

<400> 5

gccagcatca cctgctctgg agataaattg ggggataaat atgcttgctg gtatcagcag 60
aagccaggcc agtcccctgt gctggtcac tatcaagata gcaagcggcc ctcagggatc 120
cctgagcga tctctggctc caactctggg aacacagcca ctctgaccat cagcgggacc 180
caggctatgg atgaggctga ctattactgt caggcgtggg acagcagcac tgca 234

<210> 6

<211> 231
<212> DNA
<213> Homo sapiens

<400> 6
gccaacatca cctgttcttg agataaattg ggggataaat atgcttgctg gtatcagcag 60
aagccaggcc agtcccctat tctgatcatc tatcaagata acaggcggcc ctcagggatc 120
cctgagcgat tctctggctc caactctggg aacacagcca ctctgaccat cagcgggacc 180
caggctatgg atgaggctga ctattattgt caggcgtggg accgcagcac t 231

<210> 7
<211> 37
<212> DNA
<213> Homo sapiens

<400> 7
ttgggtgttc ggcggaggga ccaagctgac cgtccta 37

<210> 8
<211> 36
<212> DNA
<213> Homo sapiens

<400> 8
tgggtattcg gcggagggac ctacctgacc gtccctg 36

<210> 9
<211> 232
<212> DNA
<213> Homo sapiens

<400> 9
gccagcatca cctgctcgag agataaattg ggggaaacat atgtttcctg gtatcggcag 60
aagccaggcc agtcccctgt gctgctcatc tatcaagata ccaagcgacc ctcagggatc 120
cctgagcgat tctctggctc caactctggg aacacagccg ctctgaccat caccgggacc 180
caggcttttg atgaggctga ctattactgt caggcgtggg acagcgccac tg 232

<210> 10
<211> 37
<212> DNA
<213> Homo sapiens

<400> 10
tgtggtattc ggcggaggga ccaagctgac cgtccta 37

<210> 11
<211> 35
<212> DNA
<213> Homo sapiens

<400> 11
tggttttcgg cggagggacc aaactgacca tccta 35

<210> 12
<211> 239
<212> DNA
<213> Homo sapiens

<400> 12
gccaggatca cctgctcttg agatgcattg ccaaaaaaat atgcttattg gtaccagcag 60
aagtcaggcc aggccctgt gctgggtcatc tatgaggaca gcaaacgacc ctccgggatc 120
cctgagagat tctctggctc cagctcaggg acaatggcca ccttgactat cagtggggcc 180
caggtggagg atgaagctga ctactactgt tactcaacag acagcagtgg taatcatag 239

<210> 13
<211> 239
<212> DNA
<213> Homo sapiens

<400> 13
gccaggatca cctgctcttg agatgcattg ccaaaaaaat atgcttattg gtaccagcag 60
aagtcaggcc aggccctgt gctgggtcatc tctgaggaca gcaaacgacc ctccgggatc 120
cctgagagaa tctctggctc cagctcaggg acaatggcca ccttgactat cagtggggcc 180
caggtggaag atgaagctga ctactactgt tactcaacag acagcagttag tactcatag 239

<210> 14
<211> 34
<212> DNA
<213> Homo sapiens

<400> 14
ggtgttcggc ggagggacca agctgaccgt ccta 34

<210> 15
<211> 246
<212> DNA
<213> Homo sapiens

<400> 15
atcaccatct cctgcactgg aaccagcagt gacgttggtg gttataacta tgtctcctgg 60
taccaacagc acccaggcaa agccccaaa ctcatgattt atgaggtcag taatcggccc 120
tcaggggttt ctaatcgctt ctctggctcc aagtctggca acacggcctc cctgaccatc 180
tctgggctcc aggctgagga cgaggctgat tattactgca gctcatatac aagcagcagc 240
actctc 246

<210> 16
<211> 243
<212> DNA
<213> Homo sapiens

<400> 16
atcaccatct cctgcactgg aaccagcagt gacgttggtg gttctaactt tgtctcctgg 60
taccaacaac acccaggcaa agccccaaa ctcatgattt atgatgtcag ttatcggccc 120
tcaggggttt ctaatcgctt ctctggctcc aagtctggca acacggcctc cctgaccatc 180
tctgggctcc aggctgagga cgaggctgat tattactgca gctcatatac aagcagcagc 240
act 243

<210> 17
<211> 36
<212> DNA
<213> Homo sapiens

<400> 17
tgggtgttcg gcggaggac caagctgacc gtccta 36

<210> 18
 <211> 239
 <212> DNA
 <213> Homo sapiens

<400> 18
 gtcaggatca catgccaaagg agacagcctc agaagctatt atgcaagctg gtaccagcag 60
 aagccaggac aggcccctgt acttgtcatc tatggtaaaa acaaccggcc ctcagggatc 120
 ccagaccgat tctctggctc cagctcagga aacacagctt ccttgaccat cactggggct 180
 caggcggaag atgaggctga ctattactgt aactcccggg acagcagtgg taaccatct 239

<210> 19
 <211> 237
 <212> DNA
 <213> Homo sapiens

<400> 19
 gtcaggatca catgccaaagg agacagcctc agaagctatt atgcaagctg gttccagcag 60
 aagccaggac aggcccctgt acttgtcatc tatgctaaaa acaagcggcc ctcagggatc 120
 ccagaccgat tctctggctc cagctcagga aacacagctt ccttgaccat cactgggact 180
 caggcggaag atgaggctga ctattactgt aactcccggg acagcagtgg tgaacat 237

<210> 20
 <211> 36
 <212> DNA
 <213> Homo sapiens

<400> 20
 gtggtattcg gcggagggac caagctgacc gtccta 36

<210> 21
 <211> 246
 <212> DNA
 <213> Homo sapiens

<400> 21
 atcaccatct cctgcactgg aaccagcagt gatgttggga gttataacct tgtctcctgg 60
 taccaacagc acccaggcaa agcccccaaa ctcatgattt atgaggctcag taagcggccc 120
 tcaggggttt ctaatcgctt ctctggctcc aagtctggca acacggcctc cctgacaatc 180
 tctgggctcc aggctgagga cgaggctgat tattactgct gctcatatgc aggtagtagc 240
 actttc 246

<210> 22
 <211> 241
 <212> DNA
 <213> Homo sapiens

<400> 22
 atcaccatct cctgcactgg aaccagcagt gatgttggga gttataactt tgtctcctgg 60
 taccaactac acccaggcaa agtccccaaa ctcatgattt atgaagacat taagcggccc 120
 tcaggggttt ctaatcgctt ttctgcctcc aagtctggca acacggcctc cctgacaatc 180
 tctgggctcc aggctgagga cgaggctgat tattactgct gctcatatgc aagtcgtgac 240
 a 241

<210> 23
 <211> 38
 <212> DNA

<213> Homo sapiens

<400> 23

ggtgggtgtt cggcggaggg accaacctga ccgtccta

38

[illegible]

10. The method according to claim 7, wherein YAC-containing yeast cells are fused with HM-1 embryonic stem (ES) cells and G418 resistance colonies are picked and analysed 2-3 weeks after protoplast fusion.
11. The method according to claim 7, wherein ES cells containing a complete HuIg λ YAC copy are used for blastocyte injection to produce a chimeric animal.
12. The method according to claim 11, wherein breeding of a chimeric animal with a Balb/c mouse results in germline transmission.
13. The method according to claim 12, comprising breeding the mouse with $\kappa^{-/-}$ mice to establish lines of transgenic mice.
14. A hybridoma obtainable from a three month old HuIg λ YAC/ $\kappa^{+/-}$ mouse by fusion of splenocytes with NSO myeloma cells, and subsequent selection of single clones.
15. Antibodies obtained from a hybridoma according to claim 14.

16. A transgenic mouse comprising as a translocus a yeast artificial chromosome (YAC) of greater than 100Kb which contains a proportion of the human V λ genes proximal to the J λ -C λ cluster in germline configuration.
17. The transgenic mouse according to claim 16, wherein the YAC includes a 380 Kb region of the human Ig λ locus in authentic configuration with most V λ genes of cluster A, J λ -C λ segments and the 3' enhancer.
18. A transgenic mouse comprising variable, joining and constant genes of the human λ light chain locus as a transgenic locus on a YAC, wherein B cells of said mice rearrange said λ light chain genes and the mice express serum immunoglobulins containing human λ light chains.
19. The transgenic mouse comprising human λ light chain genes according to claim 16, wherein the λ translocus is rearranged with similar efficiency as endogenous mouse κ and at the same time as or before the endogenous κ locus.
20. The transgenic mouse comprising human λ light chain genes according to claim 16, wherein the endogenous κ locus has been silenced, and the mouse expresses serum immunoglobulins containing human λ light chains.

- 46

expresses serum immunoglobulin molecules containing human heavy chains in combination with human κ or λ light chains.

26. The transgenic mouse carrying human λ light chain genes according to claim 16, wherein expression of the endogenous mouse heavy and/or light chain loci has been prevented through gene targeting or other means and which expresses serum immunoglobulin containing human heavy and/or light chains and which are deficient in production of mouse immunoglobulin.
27. A transgenic mouse carrying human λ light chain genes in which expression of the human λ locus is equal to or greater than that of the endogenous or transgenic human κ locus.
28. The transgenic mouse carrying human λ light chain genes according to claim 27, wherein the λ translocus has been bred to homozygosity.
29. The transgenic mouse carrying human λ light chain genes according to claim 27, wherein the rearranged variable genes in the λ translocus are subject to somatic hypermutation.
30. A method for production of human antibodies comprising stimulating with antigen transgenic mice incorporating human λ light chain genes into their genome and collecting the human antibodies which bind to the antigen.

31. A method for production of human monoclonal antibodies from transgenic mice and immunised as in claim 30, by creation of hybridomas through fusion to an appropriate mouse myeloma cell line.
32. Human monoclonal antibodies comprising human heavy and light chains of diverse isotypes and chain combinations produced from transgenic mice carrying the human λ translocus.
33. Human monoclonal antibodies according to claim 32, wherein the variable regions of the human λ light chains have undergone somatic mutation.
34. Human monoclonal antibodies according to claim 32, wherein the antibodies have an affinity for antigen of greater than 10^{-8} M.